AstraZeneca
Updated
AstraZenecaa Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products
The company is promoted by AstraZeneca plc, a multinational pharmaceutical and biotechnology company headquartered in England
The company offers pharmaceutical medicines under notable brands such as Brilinta, Forxiga, Crestor, Tagrisso, Calquence, Zoladex, Symbicort, and a few more. These brands cater to various medical areas, including Cardiovascular, Renal, and Metabolic (CVRM) Diseases, Oncology, Respiratory, and Immunology, etc
FY 23 the revenue mix of the company was
Oncology - 56% in FY23 vs 47% in FY22 Cardiovascular - 27% in FY23 28% in FY22 Diabetes - 14% in FY23 vs 22% in FY22 Respiratory - 4% in FY23 vs 3% in FY22
Fundamentally- the company generates a ROCE of 30.9% > Cost of capital with Debt to equity of 0.1. PEG of 1.2 suggest stock is fairly valued
Technically- RSI above 70 suggest stock is bullish and in process of forming Cup and holder, breakout above 4920 could likely to take the stock to 6470 levels
The company is promoted by AstraZeneca plc, a multinational pharmaceutical and biotechnology company headquartered in England
The company offers pharmaceutical medicines under notable brands such as Brilinta, Forxiga, Crestor, Tagrisso, Calquence, Zoladex, Symbicort, and a few more. These brands cater to various medical areas, including Cardiovascular, Renal, and Metabolic (CVRM) Diseases, Oncology, Respiratory, and Immunology, etc
FY 23 the revenue mix of the company was
Oncology - 56% in FY23 vs 47% in FY22 Cardiovascular - 27% in FY23 28% in FY22 Diabetes - 14% in FY23 vs 22% in FY22 Respiratory - 4% in FY23 vs 3% in FY22
Fundamentally- the company generates a ROCE of 30.9% > Cost of capital with Debt to equity of 0.1. PEG of 1.2 suggest stock is fairly valued
Technically- RSI above 70 suggest stock is bullish and in process of forming Cup and holder, breakout above 4920 could likely to take the stock to 6470 levels
Note
AstraZeneca recommended at 4700, reached 5600 levels
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.